New drug aims to halt early blood cancer before it starts
NCT ID NCT03236428
First seen Mar 29, 2026 · Last updated Jun 14, 2026 · Updated 16 times
Summary
This study tests a drug called daratumumab in 42 adults with high-risk MGUS or low-risk smoldering multiple myeloma, conditions that can lead to blood cancer. The goal is to see if the drug can deeply reduce abnormal cells and prevent progression. Participants receive treatment for up to 20 cycles, and researchers track how many achieve a very good partial response or better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Karmanos Cancer Insitute
Detroit, Michigan, 48201, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
-
Pacific Cancer Care
Monterey, California, 93940, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.